Related Experiment Video

Updated: Feb 21, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.3K

Adjuvant therapy in renal cell carcinoma

Francesco Massari1, Vincenzo Di Nunno1, Chiara Ciccarese2

  • 1Division of Oncology, S.Orsola-Malpighi Hospital, Bologna, Italy.

Cancer Treatment Reviews
|October 10, 2017
PubMed

Insights

Adjuvant therapy for localized renal cell carcinoma (RCC) is under investigation. This review summarizes clinical trials of immunotherapy and targeted agents in non-metastatic RCC, highlighting their potential role in improving patient outcomes.

Area of Science:

  • Oncology
  • Nephrology
  • Pharmacology

Background:

  • Metastatic renal cell carcinoma (mRCC) treatments have advanced significantly with targeted therapies and immune-checkpoint inhibitors.
  • Key metabolic pathways in mRCC have been identified, leading to novel therapeutic strategies.
  • Despite progress in advanced disease, the role of adjuvant therapy in localized, non-metastatic RCC is not yet established.

Purpose of the Study:

  • To review current clinical trials on adjuvant therapy for renal cell carcinoma.
  • To focus on the utility of immunotherapy and targeted agents in the adjuvant setting for non-metastatic RCC.
  • To clarify the evolving treatment paradigm for localized kidney cancer.

Main Methods:

  • Systematic review of clinical trials investigating adjuvant treatments for renal cell carcinoma.
  • Focus on studies involving immunotherapy and targeted agents.
  • Analysis of data pertaining to localized, non-metastatic RCC.

Main Results:

  • Several targeted therapies and immune-checkpoint inhibitors show clinical activity in mRCC.
  • Ongoing clinical trials are actively exploring the efficacy of these agents in the adjuvant setting.
  • The precise role and benefit of adjuvant therapy in non-metastatic RCC are still under investigation.

Conclusions:

  • Adjuvant immunotherapy and targeted agents represent a promising frontier in renal cell carcinoma treatment.
  • Further research and clinical trials are crucial to define the standard of care for adjuvant therapy in localized RCC.
  • Understanding the utility of these agents may significantly alter the management of non-metastatic kidney cancer.
Keywords:
Adjuvant treatmentClear cell renal cell carcinomaImmunotherapyRenal cell carcinomaTyrosine kinases inhibitors

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.2K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.9K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
514
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
363